Energy drinks (ED) are nonalcoholic beverages that have caffeine as their most common active substance. The rapid expansion of ED consumption has created concern in the scientific community as well as in the public opinion. We report a psychotic episode probably triggered by ED abuse in a young adult without previous psychotic disorders. We have reviewed the literature regarding the relationship between caffeine, energy drinks, and psychopathology. Few articles have been published about mental health effects of energy drinks and caffeine abuse. Nevertheless, this relationship has been suggested, specifically with anxiety disorders, manic episodes, suicide attempts, psychotic decompensation, and substance use disorder. ED consumption could represent a global public health problem because of the potential severe adverse effects in mental and physical health. To our knowledge, this article is probably the first case of psychosis related to ED abuse in an individual without previous psychotic disorders.
ED constitute a relatively new product category in the wide soft drink market. The category includes a variety of nonalcoholic beverages marketed for their perceived effects as stimulants, energizers, and performance enhancers. The most common substance in ED is caffeine, which is often combined with taurine, D-glucurono-y-lactone, guaraná, maltodextrin, ginseng, carnitine, creatine, and gingko biloba; other common ingredients are vitamins and artificial and natural sweeteners [
The rapid expansion of ED consumption has created concern in the scientific community as well as in the public opinion. Available information suggests that ED consumption is becoming more and more widespread among young individuals, especially in relation to entertainment and sports practice. In the European Union, the highest prevalence of consumption was observed in the adolescent age group, with 68% having consumed at least once in 2012. However, prevalence of consumption in adults was 30% and in children was 18% [
Caffeine seems to be the main ED compound to produce a stimulant effect [
The patient was an 18-year-old Spanish male with no relevant medical or psychiatric history. Regarding his substance use, he admitted daily use of tobacco (20 cigarettes/day, meeting criteria for tobacco use disorder), daily use of cannabis (3 cannabis cigarettes/day, meeting criteria for cannabis use disorder), and occasionally weekend drinking (no meeting criteria for alcohol use disorder). He denied consumption of other psychoactive substances. As for his family background there was a paternal uncle with an unspecified chronic mental illness.
He was admitted to a psychiatry ward after presenting with an acute psychotic episode. The clinical picture included delusions of reference and persecution, pressured speech, increased alertness, fright, suspiciousness, marked anxiety, and psychomotor agitation during previous days. Hallucinations were not identified. He was aware and oriented in person, place, and time. Over the previous week, he had felt very nervous due to the proximity of high school exams. Thus, he had been drinking about 6 ED cans (80 mg caffeine per can) per day during the last seven days. Also, he had been sleeping less than three hours per night in this period, until finally he showed global insomnia during the day prior to hospital admission. He denied increasing cannabis smoking in these days or consumption of other substances.
During his first day in the inpatient unit he presented severe acute psychomotor agitation that required mechanical restraint and high doses of medication (first olanzapine 20 mg oral, followed by haloperidol 5 mg and levomepromazine 25 mg intramuscularly). After these treatments he exhibited low awareness and the ECG showed sinus bradycardia and QTc prolongation. He stayed 24 hours in the intensive care unit until his ECG was normalized and he recovered good awareness level. Urinary drug screening test was positive for cannabinoids and negative for opioids, benzodiazepines, cocaine, amphetamines, tricyclic antidepressants, and barbiturates. Additional tests (cranial CT and blood tests) were normal.
The patient returned to the psychiatry ward and was treated with olanzapine 10 mg daily and there was cessation of caffeinated drinks. After three days, psychotic symptomatology had disappeared and he was discharged with diagnosis of Substance-Induced Psychotic Disorder (according to DSM-5 classification) relative to stimulants (ED) and cannabis. He was followed up at a mental health outpatient setting with positive global evolution. He remained abstinent to cannabis and ED. Antipsychotic treatment was gradually reduced and he was finally discharged of mental health service without pharmacological treatment two years later.
Five caffeine-related syndromes are recognized in the
Caffeine-related syndromes in DSM-5 and ICD-10.
DSM-5 | ICD-10 |
---|---|
(1) Caffeine-induced sleep disorder (F15.182, F15.282, F15.982) | (1) Mental and behavioural disorders due to use of other stimulants, including caffeine (F15) |
(2) Caffeine-induced anxiety disorder (F15.180, F15.280, F15.980) | |
(3) Caffeine intoxication (F15.929) | |
(4) Caffeine withdrawal (F15.93) | |
(5) Unspecified caffeine-related disorder (F15.99) |
Caffeine intake has been linked as a potential risk factor for a wide range of psychiatric and substance use disorders. A genetic factor seems to predispose people to both caffeine intake and the risk for psychiatric disorders [
Some studies have demonstrated that the intake of large amounts of caffeine is associated with psychotic and manic symptoms and/or exacerbation of previous psychotic symptoms [
Case report evidence suggests that caffeine might induce psychotic symptoms also in some individuals without previous psychotic disorders, but this has not yet been confirmed. This may result from an exacerbation of underlying paranoid traits. Also, reduction of caffeine intake has been associated with symptom improvement in patients with psychotic disorders [
Recently, case reports of psychopathology related to ED consumption have been reported (Table
Case reports published about psychopathology related to ED consumption.
Reference | Previous mental illness | ED consumption | Psychopathology related to ED consumption | Treatment |
---|---|---|---|---|
Cruzado et al. [ | No | 4 cans of Magnus® Omnilife | Manic episode | Risperidone 3 mg/day and ED cessation |
Products + 5 coffee cups, daily, during several weeks | ||||
| ||||
Szpak and Allen [ | No | 7 cans of unspecified ED during two days | Suicide attempt | ED cessation |
| ||||
Rizkallah et al. [ | Case 1: bipolar disorder type I and cocaine dependence | 6 cans of unspecified ED, daily, during one week | Manic episode | ED cessation |
Case 2: bipolar disorder type II and cocaine dependence | 8 cans of unspecified ED, daily, during one month | Manic episode | ED cessation | |
Case 3: bipolar disorder type I, cannabis dependence, and cocaine abuse | 9 cans of unspecified ED, daily, during two weeks | Mood decompensation | ED cessation | |
| ||||
Cerimele et al. [ | Schizophrenia | 10 cans of unspecified ED, daily, during two months | Psychotic decompensation | ED cessation |
| ||||
Berigan [ | No | 6–8 cans of unspecified ED, daily, during four months | Anxiety disorder | ED cessation |
| ||||
Chelben et al. [ | Case 1: cluster B personality disorder | 5 cans of unspecified ED, daily, during 1 week | Mood decompensation | ED cessation |
Case 2: bipolar disorder, borderline personality disorder, and multiple substance abuse | 5–10 cans of unspecified ED, daily, during one month | Mood decompensation | ED cessation | |
Case 3: schizophrenia | 8-9 cans of unspecified ED, daily, during one month | Mood decompensation | ED cessation | |
| ||||
Machado-Vieira et al. [ | Bipolar disorder type I | 6 cans of Red Bull® in total during 1 week | Manic episode | ED cessation |
| ||||
Menkes [ | Schizophrenia | 5 cans of Demon Shot® in total during 1 week | Psychotic decompensation | ED cessation |
| ||||
Sharma [ | No | 6–8 cans of Red Bull (550 mL) during 1 week | Manic episode | Olanzapine 10 mg/day and ED cessation |
Initial evidence to suggest that ED use can be associated with the occurrence/reoccurrence of psychiatric symptoms comes from these case reports. Although these cases imply that excessive consumption of energy drinks may act as a trigger for relapse in certain vulnerable people with preexisting mental health problems, cases have also emerged in which serious psychiatric symptoms have occurred in otherwise healthy individuals [
In a recent study, Marmorstein [
Richards and Smith [
In this case report we hypothesize that psychotic symptoms could be related to the excessive consumption of ED during the days prior to hospitalization. Review of the topic shows similar case reports although there is not enough literature yet about the psychiatric effects of ED. Otherwise, we have to take into account other important factors that could play an important role in this case. These relevant factors are cannabis use disorder and sleep deprivation. Both have been linked with psychosis in several researches and, therefore, they have been able to contribute as etiologic and pathogenic factors.
Current cannabis abuse or dependence increases the risk of transition into psychosis in persons at ultrahigh risk of psychosis [
Excessive intake of caffeinated ED leads to sleep deprivation [
It is also remarkable that the patient suffered a severe cardiovascular complication (sinus bradycardia and QTc prolongation) after antipsychotic drug administration. A possible QTc prolongation secondary to antipsychotic drugs is well-known [
To our knowledge this case report is probably the first case of psychosis related to ED abuse in a patient without a previous diagnosis of psychotic disorder. ED abuse likely played the most important role in the pathogenesis of psychosis in this case report; however, other factors, such as cannabis use disorder, genetic factors, and sleep deprivation, were probably relevant and facilitated the process.
ED consumption could represent a global public health problem because of its potential severe adverse events. Few articles have been published on this important matter. The general public and potentially vulnerable users, such as adolescents, should be advised that caution is warranted when using these drinks, especially in large quantities over short periods of time or mixed with cannabis, alcohol, or other substances. More research is needed to determine the potential health and mental effects associated with ED consumption.
The authors declare that there are no competing interests regarding the publication of this paper.
Daniel Hernandez-Huerta conducted literature review and conceptualized and wrote the initial draft of the paper. Maria Martin-Larregola conducted literature review. Helen Dolengevich-Segal evaluated, treated, and obtained verbal informed consent of the patient. The authors Jorge Gomez-Arnau and Javier Correas-Lauffer provided substantive expertise to the conceptualization, writing, and editing of the paper. All authors contributed to and have approved the final paper.